To appraise the clinical and cost effectiveness of mepolizumab within its marketing authorisation for treating chronic obstructive pulmonary disease.
Status Awaiting development
Technology type Medicine
Decision None selected
Process STA Standard
ID number 1237

Email enquiries


Key events during the development of the guidance:

Date Update
10 August 2023 Please note that following on from information received from the company, the timelines for this appraisal have been revised and the appraisal is now anticipated to begin during early January 2025 when we will write to you about how you can get involved. The deadline for submissions is expected in approximately early March 2025.
13 December 2018 Following on from advice received from the company the timelines for this appraisal are to be aligned with the latest regulatory expectations and further information regarding the scheduling of this appraisal will be available in due course.
20 September 2017 - 18 October 2017 Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators

For further information on our processes and methods, please see our CHTE processes and methods manual